TandemViz™ 3.0: Revolutionizing Drug Discovery with an Integrated Generative AI and Physics-Based Operating System

Dec 30, 2024 18:21 CST Updated 18:21

TandemAI

Provider of Drug Discovery Platforms

In the field of drug discovery, the application of innovative AI tools acts as a catalyst for advancing the R&D process. TandemAI's self-developed one-stop drug discovery operating system, TandemViz™, integrates physical modeling and generative AI technologies. By incorporating a series of advanced algorithms, it provides comprehensive support for the entire drug discovery workflow, from target protein structure prediction, complex structure prediction and modeling, to molecular discovery, design, and optimization. This fundamentally transforms the working methods of medicinal chemists and establishes a new paradigm for drug discovery.

TandemAI Partners with IntelPharm to Launch "TandemTalk" Live Series. In the inaugural live stream, TandemAI’s product expert will provide an in-depth review of the newly upgraded TandemViz™ 3.0 version, showcasing how TandemViz™ integrates physical modeling and generative AI tools in one platform to break traditional limitations and streamline and accelerate the drug design process. You will witness how TandemViz™ covers the full spectrum of drug design from small molecules to peptides, and how its data-driven design philosophy integrates data, computational tools, and workflows to simplify complexity. We look forward to embarking on this new paradigm with you and exploring the future frontiers of drug discovery!

Live Broadcast Topic: Join hands with TandemViz™, a one-stop drug discovery operating system, to usher in a new paradigm for new drug development.

Time: January 7th, 19:00pm-20:00pm

Speaker：

Tian Chuan, Director of Applied Sciences at TandemAI

Feng Wang, Chief Researcher of Applied Science Department, TandemAI

Appointment Method: Scan the code to make an appointment and join this technological feast

Including a surprise lucky draw环节, not to be missed!

TandemViz™ 3.0 Overview of Advantages:

1.Integrated Innovation, One-Stop ServiceTandemViz™3.0 integrates TandemAI's independently developed world-class algorithms and tools to build a one-stop service platform. Researchers can complete processes from molecule generation to affinity prediction on the same platform, achieving efficient collaboration and streamlining the drug development process.

2.Intelligent Interaction, Easy Operation: The browser-based graphical interface is simple and intuitive, with convenient operation. Both novices and experts can quickly get started, facilitating drug research and development work.

3.Data-Driven, Precise Decision-Making: Data-centric, integrating data, computing tools, and workflows. Through accurate prediction, in-depth data mining, and real-time analysis, it provides precise support for R&D decision-making.

4.Evolutionary Iteration, Continuous Innovation: The platform has a strong capability for updates and iterations, continuously optimizing algorithms, expanding the functions and application scenarios of tools and solutions, and always maintaining technical leadership.

Preview of the Star Module:

TandemFEP: The Core Tool for Precise Affinity Prediction

World-class Accuracy and Throughput: An affinity prediction tool based on all-atom physics, with accuracy comparable to wet lab experiments, reaching world-leading levels in both precision and throughput. In a head-to-head comparison with Schrodinger FEP+, the predicted values show errors within 1 kcal/mol and less than 5 times the experimental error.
CBFE Innovative Functional Advantages: The unique CBFE function can predict the relative affinity of different core small molecules, construct pathways while independently calculating binding free energy, impose minimal restrictions on chemical structure changes, and consume only 1.5 times the computational power of RBFE.
Optimapper Enhances Accuracy: TandemAI’s Optimapper can automatically differentiate and define RBFE and CBFE, and by integrating CBFE and RBFE modes of calculation, significantly improves the accuracy of FEP computations.

TandemGen: A Creative Molecular Generation Factory for Expanding Chemical Space

Multiple Strategies for Molecular Generation: As a generative tool, it provides strategies such as R-group enumeration based on reaction types and fragments, scaffold hopping, and novel generative AI to rapidly create innovative small molecule structures and expand chemical space.
Strictly Filtered to Ensure Reasonable Chemical Conformation: Molecules generated are filtered through TandemAI's Tandem_Filter, jointly developed by TandemAI's pharmaceutical chemistry and computational teams, ensuring chemical reasonability. Results can be imported into other modules for further analysis, facilitating team collaboration.

TandemADMET: The Comprehensive Drug Property Prediction Master

Industry-leading accuracy: Utilizing publicly available datasets to train the ML global model, capable of predicting various ADMET property endpoints with industry-leading accuracy.
Support for personalized model training: Support for training local models based on project data and fine-tuning with data accumulation, providing property predictions that better fit the needs of drug development projects.

PepDesigner: The All-Round Partner for Peptide Drug Design

All-in-one multifunctionality: Covers pepFEP (affinity prediction for various types of peptides), pepACES (qualitative prediction of binding affinity through conformational stability analysis), pepPerm (de novo design of cyclic peptide molecules with excellent membrane permeability), pepBuilder (de novo design of peptide drugs based on the latest algorithms), and other functions, providing one-stop full-process support for peptide drug research and development.

TandemSandbox: A Treasure Box for Collaborative Innovation in Pharmaceutical Design

Convenient Interaction Design: Features innovative user interaction design and graphical interface, with analysis tools such as optimized loading structure and conformation generation, allowing experts from various fields to easily control.
Seamless Module Collaboration: Can seamlessly connect with other TandemAI modules, support complex computational analysis, promote cross-disciplinary scientific research collaboration, and spark innovation.

Free Trial of TandemViz™ 3.0, Start Now!

TandemViz™ 3.0 Free Trial Version is Now Available! Starting today, you can easily access the core features of TandemViz™ 3.0. Scan the code now to register and explore new horizons in drug discovery!

Scan to register and embark on your TandemViz™ 3.0 journey right away!

About TandemAI

TandemAI, a technology pioneer in AI for Healthcare driven by innovation, integrates generative AI and computational chemistry into traditional drug discovery workflows, aiming to become a reshaper of drug discovery infrastructure. By seamlessly integrating powerful computational tools, GPU computing resources, and large-scale chemical and biological wet labs, TandemAI provides pharmacists with a plug-and-play, one-stop solution that empowers the end-to-end early research process from hit compounds to PCC (Preclinical Candidate Compounds).

TandemAI's self-developed SaaS platform, TandemViz™, supports both cloud and private deployment, fully integrating all of TandemAI’s computational modules, data management modules, and project management modules. The data-centric design concept ensures smoother data flow, more convenient data analysis management, and enhanced team collaboration. We look forward to lowering the barriers for using the most advanced AI tools through a one-stop solution, accelerating the drug discovery process, and creating exceptional value for global partners and the scientific community.

The company was founded in October 2021 and completed a seed round and Pre-A round of financing worth 25 million US dollars invested by Capital A and Orbimed Capital by the end of the same year. Later, in March 2023, it completed a 35 million US dollar A round of financing led by Qiming Venture Partners, with Orbimed Capital, Eight Roads Ventures, and F-Prime Capital participating as follow-up investors.

Since its establishment, the company has grown to employ over 350 people in New York, Boston, Shanghai, and Suzhou, with nearly 15,000 square meters of chemistry and biology laboratories. It has provided high-quality services to more than 100 well-known biotech companies both in China and internationally, with the number of clients and projects continuing to grow. In 2023, the company was ranked on lists such as "Top 100 in China's Innovative Digital Healthcare" and "Forbes Asia's 100 Most Notable Companies in 2023."

Recommended Reading